Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1001178-90-0

Post Buying Request

1001178-90-0 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • (R)-tert-Butyl 4-(5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazine-1-carboxylate

    Cas No: 1001178-90-0

  • No Data

  • No Data

  • No Data

  • NovaChemistry
  • Contact Supplier

1001178-90-0 Usage

General Description

(R)-Tert-butyl 4-(5-Methyl-6,7-dihydro-5H-cyclopenta[d]pyriMidin-4-yl)piperazine-1-carboxylate is a chemical compound with the molecular formula C20H32N4O2. It is a piperazine derivative with a tert-butyl ester group and a cyclopenta[d]pyrimidine ring. (R)-Tert-butyl 4-(5-Methyl-6,7-dihydro-5H-cyclopenta[d]pyriMidin-4-yl)piperazine-1-carboxylate has potential pharmaceutical applications, particularly as a ligand for certain biological receptors or enzymes. Its specific properties and potential uses would depend on further research and development in the field of medicinal chemistry and drug discovery.

Check Digit Verification of cas no

The CAS Registry Mumber 1001178-90-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,0,1,1,7 and 8 respectively; the second part has 2 digits, 9 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1001178-90:
(9*1)+(8*0)+(7*0)+(6*1)+(5*1)+(4*7)+(3*8)+(2*9)+(1*0)=90
90 % 10 = 0
So 1001178-90-0 is a valid CAS Registry Number.

1001178-90-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name (R)-tert-butyl 4-(5-methyl-6,7-dihydro-5H-cyclopenta[d]-pyrimidin-4-yl)piperazine-1-carboxylate

1.2 Other means of identification

Product number -
Other names (R)-tert-butyl 4-(5-methyl-6,7-dihydro-5H-cyclopenta[d]-pyrimidin-4-yl)piperazine-1-carboxylate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1001178-90-0 SDS

1001178-90-0Relevant articles and documents

Synthesis of Akt inhibitor ipatasertib. part 1. Route scouting and early process development of a challenging cyclopentylpyrimidine intermediate

Lane, Jonathan W.,Spencer, Keith L.,Shakya, Sagar R.,Kallan, Nicholas C.,Stengel, Peter J.,Remarchuk, Travis

, p. 1641 - 1651 (2014)

Herein, the route scouting and early process development of a key cyclopentylpyrimidine ketone intermediate toward the synthesis of Akt inhibitor Ipatasertib are described. Initial supplies of the intermediate were prepared through a method that commenced with the natural product (R)-(+)-pulegone and relied on the early construction of a methyl-substituted cyclopentyl ring system. The first process chemistry route, detailed herein, enabled the synthesis of the ketone on a hundred-gram scale, but it was not feasible for the requisite production of multikilogram quantities of this compound and necessitated the exploration of alternative strategies. Several new synthetic approaches were investigated towards the preparation of the cyclopentylpyrimidine ketone, in either racemic or chiral form, which resulted in the discovery of a more practical route that hinged on the initial preparation of a highly substituted dihydroxypyrimidine compound. The cyclopentane ring in the target was then constructed through a key carbonylative esterification and subsequent tandem Dieckmann cyclization-decarboxylation sequence that was demonstrated in a racemic synthesis. This proof-of-concept was later developed into an asymmetric synthesis of the cyclopentylpyrimidine ketone, which will be described in a subsequent paper, along with the synthesis of Ipatasertib.

COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND VEMURAFENIB, AND METHODS OF USE

-

, (2012/10/18)

The invention provides a combination of a) a compound of Formula Ia: [insert Formula Ia], or a pharmaceutically acceptable salt thereof, and b) vemurafenib or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of a hy

PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS

-

Page/Page column 52, (2009/03/07)

The present invention provides compounds of Formula (I), including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1001178-90-0